secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vanda Pharmaceuticals Inc. (VNDA)
CIK:        0001347178
Form:       8-K
Filed at:   2023-12-07T23:59:59+00:00
Accession:  0001193125-23-290779
Event type: m_and_a
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 2.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vanda acquires U.S. and Canadian rights to PONVORY for $100M upfront
--------------------------------------------------------------------

- Acquired exclusive U.S. and Canadian rights to PONVORY (ponesimod), a once-daily oral S1P1R modulator for relapsing multiple sclerosis.
- Upfront cash payment of $100 million to Janssen (Johnson & Johnson); transaction closed December 7, 2023.
- Janssen will continue operations under a transitional services agreement while Vanda assumes regulatory and supply responsibility.
- Vanda CEO highlights PONVORY as a versatile immune-response modifier with potential application in autoimmune disorders beyond MS.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1347178/000119312523290779/0001193125-23-290779-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1347178/000119312523290779/d635973d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-290779

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer